Hologic, Inc. (NASDAQ:HOLX) was upgraded by equities research analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $46.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 16.37% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Bank of America Corporation cut shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $47.00 price objective on shares of Hologic in a research report on Sunday, February 5th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, February 3rd. Canaccord Genuity set a $48.00 price objective on shares of Hologic and gave the stock a “buy” rating in a research report on Monday, January 23rd. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a research report on Wednesday, January 18th. Six research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $44.47.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Shares of Hologic (NASDAQ:HOLX) opened at 39.53 on Wednesday. Hologic has a 12 month low of $32.64 and a 12 month high of $41.24. The firm has a market cap of $11.04 billion, a PE ratio of 33.79 and a beta of 1.10. The stock’s 50 day moving average is $39.90 and its 200 day moving average is $38.83.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 1st. The company reported $0.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.01. Hologic had a net margin of 11.57% and a return on equity of 27.17%. The business earned $734.40 million during the quarter, compared to analysts’ expectations of $725.01 million. During the same quarter in the prior year, the business posted $0.46 earnings per share. Hologic’s revenue was up 5.6% compared to the same quarter last year. Analysts forecast that Hologic will post $1.92 EPS for the current fiscal year.

“Needham & Company LLC Upgrades Hologic, Inc. (HOLX) to Buy” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of international trademark and copyright law. The legal version of this article can be read at http://www.dailypolitical.com/2017/02/17/needham-company-llc-upgrades-hologic-inc-holx-to-buy.html.

In other news, VP Karleen Marie Oberton sold 3,023 shares of the stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $38.32, for a total value of $115,841.36. Following the completion of the transaction, the vice president now owns 13,260 shares of the company’s stock, valued at $508,123.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elaine Ullian sold 9,423 shares of the stock in a transaction dated Friday, February 3rd. The stock was sold at an average price of $39.54, for a total transaction of $372,585.42. Following the completion of the transaction, the director now directly owns 36,798 shares of the company’s stock, valued at approximately $1,454,992.92. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of HOLX. Global X Management Co. LLC boosted its position in Hologic by 149.9% in the third quarter. Global X Management Co. LLC now owns 3,871 shares of the company’s stock worth $150,000 after buying an additional 2,322 shares during the period. Tower Research Capital LLC TRC boosted its position in Hologic by 159.1% in the third quarter. Tower Research Capital LLC TRC now owns 4,465 shares of the company’s stock worth $173,000 after buying an additional 2,742 shares during the period. Boston Advisors LLC bought a new position in Hologic during the third quarter worth approximately $202,000. Cornercap Investment Counsel Inc. bought a new position in Hologic during the fourth quarter worth approximately $202,000. Finally, Conning Inc. bought a new position in Hologic during the third quarter worth approximately $203,000. 94.09% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.